IMB is a privately held, late stage medical device company. IMB’s focus is to commercialize novel products to be used in the treatment of solid malignant and benign vascularized tumors and hypertrophic/hyperplastic tissue. The company’s core technology has been developed for the treatment of vascularized cancer tumors, uterine fibroids, and benign prostatic hyperplasia (BPH).
Our lead product, EkobiTM 500 is commercially available in Canada and the USA. It is a biodegradable embolic agent that is detectable by ultrasound. IMB’s unique product gives doctors and patients a safe and effective alternative to surgery. Embolization is a rapidly growing market and EkobiTM 500 is the only biodegradable embolic agent that is visible by ultrasound.
For more information on investor participation, please contact us.